Clinical Trial Update: AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates using plerixafor (AMD3100) with G-CSF to enhance mobilization of peripheral blood stem cells in patients with multiple myeloma or n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2010-11-25